Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Time to Market for H2S Pipeline

<< Previous

Bullboard Posts

Next >>

Comment by StockingUp21on Oct 16, 2021 5:58pm

135 Views

Post# 34014011

RE:RE:RE:RE:RE:RE:RE:RE:Time to Market for H2S Pipeline

you guys now spreading false info. If everything was this easy we should restart AME trial instead of initiate chronic baghold program

themagicbox wrote: I agree with Pez. If you're out, then be an adult and leave without spreading false info.

But since a few people have laid eyes on your false claim, I'll quickly debunk it.

In this publication, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3160634/, it demonstrated the hepatotoxicity of drugs in general with a section dedicated to NSAIDs. The hepatoxicity of other NSAIDs are in fact on par if not worse than what we have seen in this AME trial. Yet all of them are on the market.

Non-steroidal Anti-inflammatory Drugs

Due to their extensive use, non-steroidal anti-inflammatory drugs (NSAIDs) are also an important cause of hepatotoxicity.55,56 Diclofenac, the most studied in this class, is glucuronylated and also subjected to cytochrome p450-mediated reactions that result in bioactive products.57,58 Both reactive metabolites and immune mechanisms mediate toxicity. Decreased prostaglandin synthesis due to cyclooxygenase (COX) inhibition may also enhance injury. Chronic diclofenac administration may result in elevated ALT levels in the first four–six months of therapy, but severe toxicity has also been reported.59

Clearly with NSAIDs (NOT H2S), the actual mechanism of clinical benefit (COX inhibition) may contribute to DILI.

Therefore:

1- this is just literally a side effect of how all NSAIDs work to reduce inflammation

2- likely is directly correlated with efficacy, which I think is a good thing in that if the drug really is "too potent" or too long-lived via half life, reduction in dose should still be effective

Keep in mind, you dont draw conclusions from one study, but this has been reproduced time and time again. Naproxen is actually one of the worst NSAIDs in terms of GI safety. H2S solves that problem. There is no evidence to implicate the H2S is responsible for the LTEs and ALTs given the overwhelming information on hepotoxicity we have from this class of drug.

Perfection is the enemy of good, at our current point we are still strategically well placed. We solved the NSAID GI problem, this will always guarantee that the platform is worth owning. Every other issue can be managed, similar to the other drugs currently on the market.

The problem with this company is the management, especially how they execute and how they phrase their NRs. Retail market are always looking for the quick money. Make decisions on foundation not retail market senitment.

Layth1990 wrote:
We got withdrawn but the company said it nicely. If we have same lte like other naaids. The AME would be resumed. I got out with 80% loss and wont be a sheep and believe what dan rights